NeuroBo Pharma (NRBO) - Market Cap to Earnings

NeuroBo Pharmaceuticals Inc - graphic logo of issuer NRBO

NeuroBo Pharmaceuticals relies on outsourcing clinical trials to certified external laboratories to minimize operational risks. The development of neuropharmaceuticals and treatments for metabolic disorders is based on strategic partnerships with major Korean players. The business's environmental focus entails the implementation of zero-waste drug synthesis. The price characteristic (separate_pe) recorded a value of -0.90, reflecting the company's current market valuation.

neurobopharma.com (NRBO): Price to Earnings Ratio from 07/04/2022 to 12/07/2024

Comprehensive metric breakdowns and analytics for NeuroBo Pharmaceuticals (NRBO)

Comprehensive company analysis:NRBO (NeuroBo)
Original product of NeuroBo Pharma

The P/E ratio expresses the relationship between market capitalization and net income, determining the cost of one dollar of earnings. For NeuroBo Pharmaceuticals (NRBO), this metric reflects speculative expectations against the risks of clinical trial failures. By analyzing the P/E payback indicator, an investor can discern the extent of the premium paid for future successes in obesity therapy. High values signal that the share price is dependent on external financing, leaving the asset's fundamental stability in question.

Competing companies

Price to Earnings Ratio BIIB|P/E Multiple NBIX|Regencell (RGC) - Market Cap to Net Income Ratio|Price to Earnings Ratio axsome.com AXSM|P/E Multiple ACADIA Pharmaceuticals ACAD|XENE - Price to Earnings Ratio|Business Payback Period Viking Therapeutics Inc VKTX|Supernus Pharma (SUPN) - Price to Earnings Ratio|CPRX (Catalyst Pharmaceuticals) - Price to Earnings Ratio|DNLI (denalitherapeutics.com) - P/E Multiple|Price to Earnings Multiple HRMY (Harmony Biosciences Holdings, Inc.)|P/E Multiple BHVN|AMLX (Amylyx Pharmaceuticals Inc) - Company Value to Net Income|P/E Multiple TRVI (Trevi Pharma)|PRAX (Praxis Corp) - Market Cap to Net Income|anavex.com - P/E Multiple|Company Value to Net Income CBLL (CeriBell, Inc.)|PRTA: P/E Multiple|Price to Earnings Multiple ALEC|ANNX (Annexon Biosciences Inc.) - P/E Multiple|omeros.com - Market Cap to Net Income|Price to Earnings Ratio Neurogene (NGNE)|Business Payback Period AC Immune SA|P/E Multiple VYGR (voyagertherapeutics.com)|P/E Multiple Neumora NMRA|Scilex Holding - P/E Multiple|Market Cap to Earnings Tevogen Bio Inc.|Alpha Cognition (ACOG) - Price to Earnings Ratio|cogrx.com (CGTX) - P/E Multiple|Price to Earnings Ratio Inhibikase Therapeutics|Cassava (SAVA) - Business Payback Period|Price to Earnings Ratio Assertio Therapeutics (ASRT)|Business Payback Period Coya|Vistagen - Price to Earnings Ratio|Company Value to Net Income OVID|Acumen Pharmaceuticals Inc. - P/E Multiple|Market Cap to Earnings CervoMed Inc|ATHE: P/E Multiple|Price to Earnings Ratio Clene Nanomedicine|Price to Earnings Ratio PepGen Corp|Jupiter Neurosciences (JUNS) - Business Payback Period|Price to Earnings Ratio Relmada Therapeutics, Inc. (RLMD)|ANVS - Market Cap to Earnings|gracetx.com - Price to Earnings Ratio|AIFF: Price to Earnings Multiple|Klotho Neurosciences - P/E Multiple|NRSN (NeuroSense Therapeutics Ltd.) - Price to Earnings Multiple|Reviva Pharmaceuticals (RVPH) - Price to Earnings Ratio|MTVA (MetaVia Inc.) - Price to Earnings Ratio|Price to Earnings Ratio NeurAxis, Inc|Price to Earnings Ratio HSDT|P/E Multiple PASG|Business Payback Period Neuphoria Therapeutics, Inc.|minervaneurosciences.com - Price to Earnings Ratio|P/E Multiple Athira ATHA|Addex Therapeutics - P/E Multiple|ALZN - P/E Multiple|Cyclerion (CYCN) - Price to Earnings Ratio|Protagenic (PTIX) - P/E Multiple|Price to Earnings Ratio Pasithea|Price to Earnings Multiple CRGT (Cortigent)|Price to Earnings Ratio Avenue Therapeutics (ATXI)|BCLI - Market Cap to Earnings|P/E Multiple CARA (Cara Therapeutics Inc)|CHRO - Price to Earnings Ratio|ELYM: Price to Earnings Ratio|Business Payback Period Intra-Cellular Therapies, Inc. ITCI|Longboard Pharma (LBPH) - Price to Earnings Ratio|Marinus - Company Value to Net Income|Price to Earnings Ratio NKGen Biotech Inc|SAGE: Company Value to Net Income|P/E Multiple SNPX|Trevena Inc. - Price to Earnings Multiple|Price to Earnings Ratio Vigil Neuroscience, Inc. VIGL|Anew Medical, Inc. - Price to Earnings Ratio|Cerevel Therapeutics - P/E Multiple